MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
Understanding the underlying molecular mechanisms of defined cancers is crucial for effective personalized therapies. Translocations of the mixed-lineage leukemia (MLL) gene produce fusion proteins such as MLL-AF4 that disrupt epigenetic pathways and cause poor-prognosis leukemias. Here, we find tha...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Cell Press
2017
|
| _version_ | 1826279501621886976 |
|---|---|
| author | Kerry, J Godfrey, L Repapi, E Tapia, M Blackledge, N Ma, H Ballabio, E O'Byrne, S Ponthan, F Heidenreich, O Roy, A Roberts, I Konopleva, M Klose, R Geng, H Milne, T |
| author_facet | Kerry, J Godfrey, L Repapi, E Tapia, M Blackledge, N Ma, H Ballabio, E O'Byrne, S Ponthan, F Heidenreich, O Roy, A Roberts, I Konopleva, M Klose, R Geng, H Milne, T |
| author_sort | Kerry, J |
| collection | OXFORD |
| description | Understanding the underlying molecular mechanisms of defined cancers is crucial for effective personalized therapies. Translocations of the mixed-lineage leukemia (MLL) gene produce fusion proteins such as MLL-AF4 that disrupt epigenetic pathways and cause poor-prognosis leukemias. Here, we find that at a subset of gene targets, MLL-AF4 binding spreads into the gene body and is associated with the spreading of Menin binding, increased transcription, increased H3K79 methylation (H3K79me2/3), a disruption of normal H3K36me3 patterns, and unmethylated CpG regions in the gene body. Compared to other H3K79me2/3 marked genes, MLL-AF4 spreading gene expression is downregulated by inhibitors of the H3K79 methyltransferase DOT1L. This sensitivity mediates synergistic interactions with additional targeted drug treatments. Therefore, epigenetic spreading and enhanced susceptibility to epidrugs provides a potential marker for better understanding combination therapies in humans. |
| first_indexed | 2024-03-06T23:59:40Z |
| format | Journal article |
| id | oxford-uuid:757c5208-a4dd-4c3e-9f0a-7480ca10d07c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:59:40Z |
| publishDate | 2017 |
| publisher | Cell Press |
| record_format | dspace |
| spelling | oxford-uuid:757c5208-a4dd-4c3e-9f0a-7480ca10d07c2022-03-26T20:09:44ZMLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:757c5208-a4dd-4c3e-9f0a-7480ca10d07cEnglishSymplectic Elements at OxfordCell Press2017Kerry, JGodfrey, LRepapi, ETapia, MBlackledge, NMa, HBallabio, EO'Byrne, SPonthan, FHeidenreich, ORoy, ARoberts, IKonopleva, MKlose, RGeng, HMilne, TUnderstanding the underlying molecular mechanisms of defined cancers is crucial for effective personalized therapies. Translocations of the mixed-lineage leukemia (MLL) gene produce fusion proteins such as MLL-AF4 that disrupt epigenetic pathways and cause poor-prognosis leukemias. Here, we find that at a subset of gene targets, MLL-AF4 binding spreads into the gene body and is associated with the spreading of Menin binding, increased transcription, increased H3K79 methylation (H3K79me2/3), a disruption of normal H3K36me3 patterns, and unmethylated CpG regions in the gene body. Compared to other H3K79me2/3 marked genes, MLL-AF4 spreading gene expression is downregulated by inhibitors of the H3K79 methyltransferase DOT1L. This sensitivity mediates synergistic interactions with additional targeted drug treatments. Therefore, epigenetic spreading and enhanced susceptibility to epidrugs provides a potential marker for better understanding combination therapies in humans. |
| spellingShingle | Kerry, J Godfrey, L Repapi, E Tapia, M Blackledge, N Ma, H Ballabio, E O'Byrne, S Ponthan, F Heidenreich, O Roy, A Roberts, I Konopleva, M Klose, R Geng, H Milne, T MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. |
| title | MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. |
| title_full | MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. |
| title_fullStr | MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. |
| title_full_unstemmed | MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. |
| title_short | MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. |
| title_sort | mll af4 spreading identifies binding sites that are distinct from super enhancers and that govern sensitivity to dot1l inhibition in leukemia |
| work_keys_str_mv | AT kerryj mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT godfreyl mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT repapie mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT tapiam mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT blackledgen mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT mah mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT ballabioe mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT obyrnes mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT ponthanf mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT heidenreicho mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT roya mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT robertsi mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT konoplevam mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT kloser mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT gengh mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia AT milnet mllaf4spreadingidentifiesbindingsitesthataredistinctfromsuperenhancersandthatgovernsensitivitytodot1linhibitioninleukemia |